<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02886858</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00824-47</org_study_id>
    <nct_id>NCT02886858</nct_id>
  </id_info>
  <brief_title>tDCS in the Prevention of Relapse After Electroconvulsive Therapy</brief_title>
  <official_title>tDCS as Continuation Treatment to Sustain Remission After Electroconvulsive Therapy in Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital le Vinatier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital le Vinatier</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While electroconvulsive therapy (ECT) in major depression is effective, high relapse rates
      and cognitive side effects limit its long-term use. There is no consensus about optimal
      continuation pharmacological treatments after a ECT course.

      Adjunction of tDCS to pharmacological continuation treatment after ECT may decrease relapse
      rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a prospective, randomized, double blind, controlled, long-term study, investigators assign
      40 depressed patients, in remission after ECT course associated to venlafaxine, with lithium
      adjunction after ECT course, either to tDCS or sham tDCS. Depressive symptoms and cognition
      were assessed after acute ECT after six months of continuation therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse rate 6 months after remission, defined as the reappearance of a depressive syndrome, measured by a scoring MADRS &gt;15.</measure>
    <time_frame>6 months</time_frame>
    <description>MADRS will be assessed in each follow-up visit (weekly the first month, fortnightly the second and third month, monthly the following 3 months).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assesment (MoCA)</measure>
    <time_frame>basal and at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scores on Clinical Global Impression (CGI)</measure>
    <time_frame>after remission basal and at 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>during 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device : Transcranial direct current stimulation</intervention_name>
    <description>The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.</description>
    <arm_group_label>tDCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Device : sham Transcranial direct current stimulation</intervention_name>
    <description>The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.</description>
    <arm_group_label>Sham tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 ans

          -  Remission (MADRS &lt;10) of a major depressive episode after acute treatment with ECT +
             venlafaxine

          -  Lithium adjunction 48h after the last ECT session

          -  No comorbid psychiatric disorder, excluding personality disorder or nicotine
             dependance.

          -  Capacity to consent

          -  Sufficient comprehension of the French language

        Exclusion Criteria:

          -  Contra-indications to tDCS

          -  Neurologic conditions

          -  Severe medical conditions.

          -  Pregnancy/breast-feeding.

          -  Current use of benzodiazepines or antipsychotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GALVAO FILIPE, PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH LE VINATIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GALVAO FILIPE, PH</last_name>
    <phone>0437915451</phone>
    <email>filipe.galvao@ch-le-vinatier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VIAL VERONIQUE</last_name>
    <email>veronique.vial@ch-le-vinatier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Hospitalier Le Vinatier</name>
      <address>
        <city>Bron</city>
        <state>Rhône Alpes</state>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VIAL VERONIQUE</last_name>
      <phone>0033437915531</phone>
      <email>veronique.vial@ch-le-vinatier.fr</email>
    </contact>
    <contact_backup>
      <last_name>GALVAO FILIPE, PH</last_name>
      <phone>0033437915565</phone>
      <email>filipe.galvao@ch-le-vinatier.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2016</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Moods disorders</keyword>
  <keyword>electroconvulsive therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

